Accéder directement au contenu Accéder directement à la navigation
Article dans une revue

Protection by Metformin against Severe Covid-19: An in-Depth Mechanistic Analysis.

Abstract : Since the outbreak of Covid-19, several observational studies on diabetes and Covid-19 have reported a favourable association between metformin and Covid-19-related outcomes in patients with type 2 diabetes mellitus (T2DM). This is not surprising since metformin affects many of the pathophysiological mechanisms implicated in SARS-CoV-2 immune response, systemic spread and sequelae. A comparison of the multifactorial pathophysiological mechanisms of Covid-19 progression with metformin's well-known pleiotropic properties suggests that the treatment of patients with this drug might be particularly beneficial. Indeed, metformin could alleviate the cytokine storm, diminish virus entry into cells, protect against microvascular damage as well as prevent secondary fibrosis. Although our in-depth analysis covers many potential metformin mechanisms of action, we want to highlight more particularly its unique microcirculatory protective effects since worsening of Covid-19 disease clearly appears as largely due to severe defects in the structure and functioning of microvessels. Overall, these observations confirm that metformin is a unique, pleiotropic drug that targets many of Covid-19's pathophysiology processes in a diabetes-independent manner.
Type de document :
Article dans une revue
Liste complète des métadonnées

https://hal-u-picardie.archives-ouvertes.fr/hal-03692966
Contributeur : Louise DESSAIVRE Connectez-vous pour contacter le contributeur
Soumis le : vendredi 10 juin 2022 - 10:32:44
Dernière modification le : samedi 25 juin 2022 - 03:53:05

Lien texte intégral

Identifiants

Citation

Nicolas Wiernsperger, Abdallah Al-Salameh, Bertrand Cariou, Jean-Daniel Lalau. Protection by Metformin against Severe Covid-19: An in-Depth Mechanistic Analysis.. Diabetes & metabolism, 2022, pp.101359. ⟨10.1016/j.diabet.2022.101359⟩. ⟨hal-03692966⟩

Partager

Métriques

Consultations de la notice

0